Trial Profile
Clinical outcomes crohn's disease and ulcerative colitis patients treated with adalimumab and infliximab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 08 Sep 2017 New trial record